Lopinavir
| Clinical data | |
|---|---|
| Pronunciation | /loʊˈpɪnəvɪər/ loh-PIN-ə-veer | 
| Other names | ABT-378 | 
| AHFS/Drugs.com | International Drug Names | 
| MedlinePlus | a602015 | 
| License data | |
| Routes of administration | By mouth | 
| ATC code | 
 | 
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Unknown | 
| Protein binding | 98-99% | 
| Metabolism | Liver | 
| Elimination half-life | 5 to 6 hours | 
| Excretion | Mostly fecal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.281.362 | 
| Chemical and physical data | |
| Formula | C37H48N4O5 | 
| Molar mass | 628.814 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir).
It was patented in 1995 and approved for medical use in 2000. Considered now as second-line therapy in the West, it is still prescribed in LMIC, especially among children living with HIV. Lopinavir and ritonavir can be taken as a tablet or an oral solution, a preferred option in children. In the early stages of COVID-19 pandemics, lopinavir was repurposed against the SARS-CoV-2 virus in the hope of disturbing its protease activity.